AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Refractory Autoimmune Diseases

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site๐Ÿ“ Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 cell Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497387EARLY Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: PRG-1801 BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: BCMA-CD19 CAR-T therapy A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases NCT06980597Phase 12 sites๐Ÿ“ Beijing๐Ÿ“ Beijing Beijing GoBroad Hospital ยท Tests: OL-108 Treatment of Moderate to Severe Refractory Crohn's Disease NCT06721962Phase 1, Phase 213 sites๐Ÿ“ Scottsdale๐Ÿ“ Sacramento๐Ÿ“ San Francisco Tr1X, Inc. ยท Tests: TRX103, Cyclophosphamide CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus NCT07855302Phase 11 site๐Ÿ“ Seoul Seoul National University Hospital ยท Tests: SNUH-CD19-CAR-T Cells, Lymphodepleting Chemotherapy CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: UCAR T-cell Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease NCT07129642EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Zhongshan Hospital ยท Tests: Allogeneic CAR-T Safety Study of CC312 in Autoimmune Disease Patients NCT06888960EARLY Phase 11 site๐Ÿ“ Tianjin CytoCares Inc ยท Tests: CC312 Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus NCT06585514Phase 1, Phase 21 site๐Ÿ“ Beijing Beijing GoBroad Hospital ยท Tests: CD19 CAR-T cells A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus NCT07339332EARLY Phase 11 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: CAR-T Therapy Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus NCT06691152Phase 11 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ ยท Tests: CD19 Universal CAR-T cells Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases NCT07322718EARLY Phase 11 site๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: RXIM002 product Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis NCT07796516Phase 247 sites๐Ÿ“ Hefei๐Ÿ“ Hefei๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Telitacicept 160mg, Standard therapy A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases NCT07104721Phase 11 site๐Ÿ“ Hefei China Immunotech (Beijing) Biotechnology Co., Ltd. ยท Tests: YTS109 cell Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE NCT07031713Phase 11 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: CAR-T Therapy Immune Profiling of Refractory cSLE Exposed to CD3ร—CD19 BiTE NCT07352332n/a1 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease NCT07547930Phase 21 site๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: Tofacitinib Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases NCT07301164EARLY Phase 11 site๐Ÿ“ Beijing Peking University Third Hospital ยท Tests: BCT301 Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE NCT07233642Phase 11 site๐Ÿ“ Hangzhou The Children's Hospital of Zhejiang University School of Meโ€ฆ ยท Tests: CD19 CAR-T cells Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis NCT07491016n/a1 site๐Ÿ“ Hangzhou Zhejiang Provincial People's Hospital Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases NCT07121777NA1 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment NCT07304154Phase 110 sites๐Ÿ“ Newport Beach๐Ÿ“ Palo Alto๐Ÿ“ New York Kite, A Gilead Company ยท Tests: KITE-363, Fludarabine, Cyclophosphamide Study of CD19 CAR-T Therapy for Refractory SLE NCT07403097Phase 11 site๐Ÿ“ Chongqing Chongqing Precision Biotech Co., Ltd ยท Tests: PTOC1 A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis NCT07412704Phase 1, Phase 239 sites๐Ÿ“ La Jolla๐Ÿ“ Loma Linda๐Ÿ“ Palo Alto Bristol-Myers Squibb ยท Tests: BMS-986528 An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Cell Therapy Group Co.,Ltd ยท Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497361EARLY Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: PRG-2311 A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases NCT07413341Phase 11 site๐Ÿ“ Shanghai Therorna ยท Tests: TI-0032-III injection IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE) NCT07617740EARLY Phase 11 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: IASO207 Injection CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases NCT07337785EARLY Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: CD19/BCMA-targeted CAR-T cells, Lymphodepleting Conditioning
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy